

Peter Hohenberger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/171914/publications.pdf>

Version: 2024-02-01

80
papers

5,533
citations

201385

27
h-index

82410

72
g-index

81
all docs

81
docs citations

81
times ranked

6422
citing authors

#	ARTICLE	IF	CITATIONS
1	Financial toxicity in sarcoma patients and survivors in Germany: results from the multicenter PROSa study. <i>Supportive Care in Cancer</i> , 2022, 30, 187-196.	1.0	10
2	Dual-Energy CT Vital Iodine Tumor Burden for Response Assessment in Patients With Metastatic GIST Undergoing TKI Therapy: Comparison With Standard CT and FDG PET/CT Criteria. <i>American Journal of Roentgenology</i> , 2022, 218, 659-669.	1.0	8
3	Diagnosis strategy of adipocytic soft-tissue tumors in adults: a consensus from European experts. <i>European Journal of Surgical Oncology</i> , 2022, 48, 518-525.	0.5	12
4	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	3.2	18
5	The association of Health-Related Quality of Life and 1-year-survival in sarcoma patients—results of a Nationwide Observational Study (PROSa). <i>British Journal of Cancer</i> , 2022, 126, 1346-1354.	2.9	6
6	Clinical value of pre-operative scoring systems to predict leiomyosarcoma: results of a validation study in 177 patients from the NOGGO-REGSA Registry. <i>International Journal of Gynecological Cancer</i> , 2022, , ijgc-2021-003334.	1.2	3
7	Selective internal radioembolization (SIRT) allows to control liver metastases of gastrointestinal stromal tumors (GIST) failing treatment with tyrosine kinase inhibitors (TKI).. <i>Journal of Clinical Oncology</i> , 2022, 40, 11540-11540.	0.8	0
8	Abstract 4139: Dual energy analysis of TKI response in GIST - results of a prospective trial. <i>Cancer Research</i> , 2022, 82, 4139-4139.	0.4	0
9	Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study. <i>Oncology Research and Treatment</i> , 2021, 44, 301-312.	0.8	13
10	Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy. <i>Cancers</i> , 2021, 13, 586.	1.7	10
11	Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 <i>Cancers</i> , 2021, 13, 1223.	1.7	15
12	First report on establishment and characterization of a carcinosarcoma tumour cell line model of the bladder. <i>Scientific Reports</i> , 2021, 11, 6030.	1.6	5
13	Gene Expression in Solitary Fibrous Tumors (SFTs) Correlates with Anatomic Localization and NAB2-STAT6 Gene Fusion Variants. <i>American Journal of Pathology</i> , 2021, 191, 602-617.	1.9	30
14	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	2.0	96
15	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. <i>Cancer Discovery</i> , 2021, 11, 2780-2795.	7.7	125
16	Molecular and Pathological Profiling of Corresponding Treatment-Naïve and Neoadjuvant Pazopanib-Treated High-Risk Soft Tissue Sarcoma Samples of the GISG-04/NOPASS Study. <i>Biology</i> , 2021, 10, 639.	1.3	1
17	Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2173-2181.	0.5	2
18	Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa). <i>European Journal of Cancer Care</i> , 2021, 30, e13484.	0.7	7

#	ARTICLE	IF	CITATIONS
19	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3128-3139.	0.8	56
20	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498.	5.8	237
21	Computer tomography guided thoracoscopic resection of small pulmonary nodules in the hybrid theatre. <i>PLoS ONE</i> , 2021, 16, e0258896.	1.1	5
22	Accuracy and Safety of Ultrasound-Guided Core Needle Biopsy of Soft Tissue Tumors in an Outpatient Setting: A Sarcoma Center Analysis of 392 Consecutive Patients. <i>Cancers</i> , 2021, 13, 5659.	1.7	5
23	Impact of preoperative treatment on the CINSARC prognostic signature: translational research results from a phase I trial of the German Interdisciplinary Sarcoma Group (GISG 03). <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 280-285.	1.0	1
24	The challenge of treating elderly patients with advanced bone and soft tissue sarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 155, 103108.	2.0	8
25	Prognosis of Patients with Metastatic Soft Tissue Sarcoma: Advances in Recent Years. <i>Oncology Research and Treatment</i> , 2020, 43, 613-619.	0.8	32
26	Career and Financial Situation of Patients Diagnosed with Soft Tissue Sarcomas. <i>Oncology Research and Treatment</i> , 2020, 43, 539-548.	0.8	4
27	Definition and severity grading of postoperative lymphatic leakage following inguinal lymph node dissection. <i>Langenbeck's Archives of Surgery</i> , 2020, 405, 697-704.	0.8	8
28	The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany – Cross-Sectional Results of a Nationwide Observational Study (PROSa). <i>Cancers</i> , 2020, 12, 3590.	1.7	31
29	Fusion imaging to evaluate the radiographic anatomical relationship between primary tumors and local recurrences in retroperitoneal soft tissue sarcoma. <i>Surgical Oncology</i> , 2020, 34, 109-112.	0.8	2
30	Familial adenomatous polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. <i>ESMO Open</i> , 2020, 5, e000604.	2.0	11
31	Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. <i>JAMA Surgery</i> , 2020, 155, e200397.	2.2	29
32	Core needle biopsy versus incisional biopsy for differentiation of soft tissue sarcomas: A systematic review and meta-analysis. <i>Cancer</i> , 2020, 126, 1917-1928.	2.0	46
33	MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of ⁶⁸ Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1749-1755.	2.8	27
34	Lower-dosing ponatinib in pre-treated GIST: Results of the POETIG phase II trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 11536-11536.	0.8	3
35	NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2/3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 1148-1159.	5.1	288
36	Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study. <i>European Journal of Cancer</i> , 2019, 120, 47-53.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Current State of Sarcoma Care in Germany: Results of an Online Survey of Physicians. <i>Oncology Research and Treatment</i> , 2019, 42, 589-598.	0.8	5
38	Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic 18F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group. <i>Cancers</i> , 2019, 11, 790.	1.7	11
39	Preoperative Pazopanib in High-Risk Soft Tissue Sarcoma: Phase II Window-of Opportunity Study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04). <i>Annals of Surgical Oncology</i> , 2019, 26, 1332-1339.	0.7	12
40	Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST). <i>International Journal of Cancer</i> , 2019, 145, 2292-2303.	2.3	21
41	Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2019, 125, 1290-1300.	2.0	71
42	The evaluation of circulating endothelial progenitor cells and related angiogenic markers as prognostic factors in soft-tissue tumors. <i>European Journal of Surgical Oncology</i> , 2018, 44, 496-501.	0.5	3
43	Integrative genomic and transcriptomic analysis of leiomyosarcoma. <i>Nature Communications</i> , 2018, 9, 144.	5.8	197
44	Strengthening health data on a rare and heterogeneous disease: sarcoma incidence and histological subtypes in Germany. <i>BMC Public Health</i> , 2018, 18, 235.	1.2	64
45	Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma. <i>Annals of Surgery</i> , 2018, 267, 959-964.	2.1	142
46	Neoadjuvant Therapy to Downstage the Extent of Resection of Gastrointestinal Stromal Tumors. <i>Visceral Medicine</i> , 2018, 34, 359-365.	0.5	21
47	Clinical Presentation of Gastrointestinal Stromal Tumors. <i>Visceral Medicine</i> , 2018, 34, 335-340.	0.5	42
48	Standard Approach to Gastrointestinal Stromal Tumors - Differences between China and Europe. <i>Visceral Medicine</i> , 2018, 34, 353-358.	0.5	8
49	Regional chemotherapy by isolated limb perfusion prior to surgery compared with surgery and post-operative radiotherapy for primary, locally advanced extremity sarcoma: a comparison of matched cohorts. <i>Clinical Sarcoma Research</i> , 2018, 8, 12.	2.3	18
50	Treatment of angiosarcoma with pazopanib and paclitaxel: Results of the phase II trial of the German Interdisciplinary Sarcoma Group (GISG-06 EVA) study. <i>Journal of Clinical Oncology</i> , 2018, 36, 11570-11570.	0.8	2
51	Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Transatlantic RPS Working Group. <i>Cancer</i> , 2017, 123, 1971-1978.	2.0	104
52	Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). <i>European Journal of Cancer</i> , 2017, 76, 60-67.	1.3	88
53	Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review. <i>Clinical and Translational Imaging</i> , 2017, 5, 183-197.	1.1	59
54	Transplanted Fibroblasts Proliferate in Host Bronchial Tissue and Enhance Bronchial Anastomotic Healing in a Rodent Model. <i>International Journal of Artificial Organs</i> , 2017, 40, 515-521.	0.7	0

#	ARTICLE	IF	CITATIONS
55	Increased cFLIP expression in thymic epithelial tumors blocks autophagy via NF- κ B signalling. <i>Oncotarget</i> , 2017, 8, 89580-89594.	0.8	12
56	Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS). <i>BMJ Open</i> , 2016, 6, e009558.	0.8	9
57	Combined sunitinib and radiation therapy for preoperative treatment of soft tissue sarcoma: results of a phase I trial of the German interdisciplinary sarcoma group (GISG-03). <i>Radiation Oncology</i> , 2016, 11, 77.	1.2	22
58	Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma. <i>Cancer</i> , 2016, 122, 2624-2632.	2.0	38
59	Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01). <i>Annals of Surgical Oncology</i> , 2016, 23, 1924-1927.	0.7	58
60	Primary and secondary angiosarcomas: a comparative single-center analysis. <i>Clinical Sarcoma Research</i> , 2015, 5, 14.	2.3	16
61	Combination of Trabectedin and Gemcitabine for Advanced Soft Tissue Sarcomas: Results of a Phase I Dose Escalating Trial of the German Interdisciplinary Sarcoma Group (GISG). <i>Marine Drugs</i> , 2015, 13, 379-388.	2.2	9
62	In vivo Quantification of the Effects of Radiation and Presence of Hair Follicle Pores on the Proliferation of Fibroblasts in an Acellular Human Dermis in a Dorsal Skinfold Chamber: Relevance for Tissue Reconstruction following Neoadjuvant Therapy. <i>PLoS ONE</i> , 2015, 10, e0125689.	1.1	2
63	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. <i>Journal of Clinical Oncology</i> , 2015, 33, 4276-4283.	0.8	148
64	Trabectedin: adding clarification rather than novelty. <i>Lancet Oncology</i> , The, 2015, 16, 353-354.	5.1	0
65	Effect of dynamic seeding methods on the distribution of fibroblasts within human acellular dermis. <i>Cell and Tissue Banking</i> , 2015, 16, 605-614.	0.5	14
66	Collaborations Between SSO and the Connective Tissue Oncology Society (CTOS) Series. <i>Annals of Surgical Oncology</i> , 2015, 22, 2815-2816.	0.7	1
67	Objective and Subjective Image Quality of Liver Parenchyma and Hepatic Metastases with Virtual Monoenergetic Dual-source Dual-energy CT Reconstructions. <i>Academic Radiology</i> , 2014, 21, 514-522.	1.3	56
68	Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSC Experience. <i>Annals of Surgical Oncology</i> , 2013, 20, 2937-2943.	0.7	190
69	Surgical Management and Minimally Invasive Approaches for the Treatment of Metastatic Sarcoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 457-464.	1.8	7
70	Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2012, 379, 1879-1886.	6.3	1,752
71	One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1265.	3.8	832
72	Neoadjuvant treatment of locally advanced GIST: Results of APOLLON, a prospective, open label phase II study in KIT- or PDGFRA-positive tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10031-10031.	0.8	32

#	ARTICLE	IF	CITATIONS
73	Angiosarcoma: State of the art and perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 257-263.	2.0	95
74	Role of Surgery Combined with Kinase Inhibition in the Management of Gastrointestinal Stromal Tumor (GIST). <i>Annals of Surgical Oncology</i> , 2010, 17, 2585-2600.	0.7	39
75	Adjuvant treatment of GIST with imatinib: Solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). <i>European Journal of Cancer</i> , 2009, 45, 1103-1106.	1.3	31
76	Adjuvant imatinib in GIST: a self-fulfilling prophecy, or more?. <i>Lancet, The</i> , 2009, 373, 1058-1060.	6.3	12
77	The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction. <i>World Journal of Surgical Oncology</i> , 2008, 6, 37.	0.8	21
78	Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors?. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 240-241.	4.3	2
79	Surgical interventions in patients with hematologic malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 55, 83-91.	2.0	21
80	Tumor recurrence and options for further treatment after resection of liver metastases in patients with colorectal cancer. <i>Journal of Surgical Oncology</i> , 1990, 44, 245-251.	0.8	84